Managing post-PRK discomfort

Article

When treating post-phacorefractive keratectomy (PRK) discomfort, there are no significant differences in either safety or efficacy between bromfenac twice-daily and ketorolac four times daily, according to a study published in the February issue of the Journal of Refractive Surgery.

When treating post-phacorefractive keratectomy (PRK) discomfort, there are no significant differences in either safety or efficacy between bromfenac twice-daily and ketorolac four times daily, according to a study published in the February issue of the Journal of Refractive Surgery.

Neal A. Sher, MD, FACS - of the Department of Ophthalmology at the University of Minnesota Medical School, Minneapolis, US - and colleagues compared the two NSAIDs in terms of post-PRK prevention of pain, foreign body sensation, burning and light sensitivity, as well as epithelial healing rates by randomizing eyes (n=212) to receive one of the anti-inflammatories (bromfenac, n=105; ketorolac, n=107) in an open label trial. Any patient having two eyes treated received both medications, one for each eye. All eyes underwent PRK with the same technique, and were then fitted with the Acuvue Oasys bandage contact lens (Johnson & Johnson Vision Care) before receiving either bromfenac or ketorolac. Postoperatively, patients also received BSS, prednisolone acetate 1.0%, gatifloxacin ophthalmic solution 0.3% and, for some patients, mitomycin C 0.02%.

The drugs had similar epithelial healing rates, and neither was associated with a drug-related adverse event. Between the two drug populations, the research team did not note any significant differences in postoperative pain, burning, foreign body sensation or photophobia.

The team concluded that, following the usual post-PRK safety measures including application of cold BSS and use of a bandage contact lens, there are no differences in discomfort reduction between bromfenac twice daily and ketorolac four times daily.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.